Dimerix activates first paediatric clinical site and appoints expert paediatric nephrologist

Dimerix Limited (ASX:DXB) has activated the first clinical site specializing in paediatric kidney disease in Mexico, allowing for the active recruitment of adolescent patients into the ACTION3 Phase 3 clinical trial. The company also announced the appointment of Dr Howard Trachtman, an expert paediatric nephrologist, to its Medical Advisory Board.

Dr David Fuller and Dr Howard Trachtman on the recent developments

Dr David Fuller, Chief Medical Officer at Dimerix, expressed his delight at the initiation of the first paediatric site in Mexico, marking a new milestone for the ACTION3 study. He emphasized the importance of drawing on the expertise and professional networks of Dr Trachtman as the company continues to focus on the recruitment goals of this pivotal study. Dr Howard Trachtman, NYU School of Medicine, Paediatric Department; Adjunct Professor of Paediatric Nephrology, University of Michigan, highlighted the potential of DMX-200 in treating patients of all ages with FSGS, emphasizing its suitability for use in both children and adults.

Summary of recent developments and outlook

Dimerix has made significant progress with the activation of the first paediatric clinical site in Mexico and the appointment of Dr Howard Trachtman to its Medical Advisory Board. The company remains on-track with recruitment for the ACTION3 Phase 3 clinical trial, with the interim analysis expected around mid-2025. The cash position to fund the ongoing study remains strong, providing a solid foundation for the company's future endeavors. With the potential expansion of DMX-200's approval to adolescents in key territories, including the US and Europe, Dimerix aims to address the unmet medical needs in paediatric patients with FSGS. The appointment of Dr Trachtman further strengthens the company's expertise in paediatric nephrology, reflecting its commitment to advancing innovative therapies for kidney diseases.